Published in Clin Exp Metastasis on January 01, 2002
CCL2 is a potent regulator of prostate cancer cell migration and proliferation. Neoplasia (2006) 2.05
CC chemokine ligand 2 (CCL2) promotes prostate cancer tumorigenesis and metastasis. Cytokine Growth Factor Rev (2009) 1.93
CCL2 as an important mediator of prostate cancer growth in vivo through the regulation of macrophage infiltration. Neoplasia (2007) 1.91
Multiple roles of chemokine (C-C motif) ligand 2 in promoting prostate cancer growth. J Natl Cancer Inst (2010) 1.74
CCL2 protects prostate cancer PC3 cells from autophagic death via phosphatidylinositol 3-kinase/AKT-dependent survivin up-regulation. J Biol Chem (2008) 1.71
Stepping out of the flow: capillary extravasation in cancer metastasis. Clin Exp Metastasis (2007) 1.68
Wnts induce migration and invasion of myeloma plasma cells. Blood (2005) 1.58
Chemokines, chemokine receptors and adhesion molecules on different human endothelia: discriminating the tissue-specific functions that affect leucocyte migration. Clin Exp Immunol (2003) 1.39
Systemic delivery of neutralizing antibody targeting CCL2 for glioma therapy. J Neurooncol (2010) 1.19
Targeting chemokine (C-C motif) ligand 2 (CCL2) as an example of translation of cancer molecular biology to the clinic. Prog Mol Biol Transl Sci (2010) 1.14
Mouse models as a translational platform for the development of new therapeutic agents in multiple myeloma. Curr Cancer Drug Targets (2012) 0.97
Osteoclast-gene expression profiling reveals osteoclast-derived CCR2 chemokines promoting myeloma cell migration. Blood (2010) 0.93
Synergy between anti-CCL2 and docetaxel as determined by DW-MRI in a metastatic bone cancer model. J Cell Biochem (2009) 0.88
Smac Mimetic-Induced Upregulation of CCL2/MCP-1 Triggers Migration and Invasion of Glioblastoma Cells and Influences the Tumor Microenvironment in a Paracrine Manner. Neoplasia (2015) 0.82
Mechanisms involved in the differential bone marrow homing of CD45 subsets in 5T murine models of myeloma. Clin Exp Metastasis (2002) 0.81
Macrophage chemotactic protein-1 mRNA levels in non-Hodgkin lymphoma. Clin Exp Med (2010) 0.80
Part of the multiple myeloma-associated microvessels is functionally connected to the systemic circulation: a study in the murine 5T33MM model. Virchows Arch (2004) 0.78
Integrated pharmacokinetic, pharmacodynamic and immunogenicity profiling of an anti-CCL21 monoclonal antibody in cynomolgus monkeys. MAbs (2015) 0.75
Lymphocyte homing and homeostasis. Science (1996) 13.26
Human monocyte chemoattractant protein-1 (MCP-1). Immunol Today (1990) 3.31
Idiopathic paraproteinemia. II. Transplantation of the paraprotein-producing clone from old to young C57BL/KaLwRij mice. J Immunol (1979) 2.60
Monocyte chemotactic and activating factor gene expression induced in endothelial cells by IL-1 and tumor necrosis factor. J Immunol (1990) 2.10
Evidence that multiple myeloma Ig heavy chain VDJ genes contain somatic mutations but show no intraclonal variation. Blood (1992) 1.42
Organ involvement and phenotypic adhesion profile of 5T2 and 5T33 myeloma cells in the C57BL/KaLwRij mouse. Br J Cancer (1997) 1.30
The 5TMM series: a useful in vivo mouse model of human multiple myeloma. Hematol J (2000) 1.25
Characterization of the CCR2 chemokine receptor: functional CCR2 receptor expression in B cells. J Immunol (1997) 1.22
Transendothelial migration of CD34+ and mature hematopoietic cells: an in vitro study using a human bone marrow endothelial cell line. Blood (1997) 1.07
Selective transendothelial migration of hematopoietic progenitor cells: a role in homing of progenitor cells. Blood (1999) 0.97
Selective initial in vivo homing pattern of 5T2 multiple myeloma cells in the C57BL/KalwRij mouse. Br J Cancer (2000) 0.96
Insulin-like growth factor-1 acts as a chemoattractant factor for 5T2 multiple myeloma cells. Blood (1999) 0.87
Identification of IL-1beta-induced messenger RNAs in rat pancreatic beta cells by differential display of messenger RNA. Diabetologia (1999) 0.79
Hyperproliferative apoptosis-resistant endothelial cells in idiopathic pulmonary arterial hypertension. Am J Physiol Lung Cell Mol Physiol (2007) 3.28
Free fatty acids and cytokines induce pancreatic beta-cell apoptosis by different mechanisms: role of nuclear factor-kappaB and endoplasmic reticulum stress. Endocrinology (2004) 3.03
Report of the European Myeloma Network on multiparametric flow cytometry in multiple myeloma and related disorders. Haematologica (2008) 2.99
Initiation and execution of lipotoxic ER stress in pancreatic beta-cells. J Cell Sci (2008) 2.99
Somatic chromosome abnormalities in the lungs of patients with pulmonary arterial hypertension. Am J Respir Crit Care Med (2010) 2.09
Hypoxia-inducible factors in human pulmonary arterial hypertension: a link to the intrinsic myeloid abnormalities. Blood (2011) 2.08
Zoledronic acid treatment of 5T2MM-bearing mice inhibits the development of myeloma bone disease: evidence for decreased osteolysis, tumor burden and angiogenesis, and increased survival. J Bone Miner Res (2003) 1.82
PTPN2, a candidate gene for type 1 diabetes, modulates interferon-gamma-induced pancreatic beta-cell apoptosis. Diabetes (2009) 1.63
Discovery of gene networks regulating cytokine-induced dysfunction and apoptosis in insulin-producing INS-1 cells. Diabetes (2003) 1.63
Clinical significance of chemokine receptor (CCR1, CCR2 and CXCR4) expression in human myeloma cells: the association with disease activity and survival. Haematologica (2006) 1.62
Glucagon-like peptide-1 agonists protect pancreatic beta-cells from lipotoxic endoplasmic reticulum stress through upregulation of BiP and JunB. Diabetes (2009) 1.50
Mesenchymal stem cell adhesion to cardiac microvascular endothelium: activators and mechanisms. Am J Physiol Heart Circ Physiol (2005) 1.49
Targeting the multiple myeloma hypoxic niche with TH-302, a hypoxia-activated prodrug. Blood (2010) 1.48
Effect of sample dilution on serum free light chain concentration by immunonephelometric assay. Clin Chim Acta (2011) 1.48
Is there a role for locally produced interleukin-1 in the deleterious effects of high glucose or the type 2 diabetes milieu to human pancreatic islets? Diabetes (2005) 1.45
Migration of culture-expanded human mesenchymal stem cells through bone marrow endothelium is regulated by matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-3. Haematologica (2007) 1.44
Recombinant osteoprotegerin decreases tumor burden and increases survival in a murine model of multiple myeloma. Cancer Res (2003) 1.41
Expression of adiponectin receptors in pancreatic beta cells. Biochem Biophys Res Commun (2003) 1.41
1,25-Dihydroxyvitamin D3 modulates expression of chemokines and cytokines in pancreatic islets: implications for prevention of diabetes in nonobese diabetic mice. Endocrinology (2005) 1.39
Cytokine-induced proapoptotic gene expression in insulin-producing cells is related to rapid, sustained, and nonoscillatory nuclear factor-kappaB activation. Mol Endocrinol (2006) 1.39
Corneal myofibroblast generation from bone marrow-derived cells. Exp Eye Res (2010) 1.31
Multiple myeloma biology: lessons from the 5TMM models. Immunol Rev (2003) 1.27
Human primary lung endothelial cells in culture. Am J Respir Cell Mol Biol (2012) 1.24
An update on lipotoxic endoplasmic reticulum stress in pancreatic beta-cells. Biochem Soc Trans (2008) 1.22
Transcriptional regulation of the endoplasmic reticulum stress gene chop in pancreatic insulin-producing cells. Diabetes (2007) 1.22
Cross-talk between vascular endothelial growth factor and matrix metalloproteinases in the induction of neovascularization in vivo. Am J Pathol (2009) 1.17
Death protein 5 and p53-upregulated modulator of apoptosis mediate the endoplasmic reticulum stress-mitochondrial dialog triggering lipotoxic rodent and human β-cell apoptosis. Diabetes (2012) 1.16
Role of CCR1 and CCR5 in homing and growth of multiple myeloma and in the development of osteolytic lesions: a study in the 5TMM model. Clin Exp Metastasis (2006) 1.16
Role of the hypoxic bone marrow microenvironment in 5T2MM murine myeloma tumor progression. Haematologica (2005) 1.14
Inhibiting the IGF-1 receptor tyrosine kinase with the cyclolignan PPP: an in vitro and in vivo study in the 5T33MM mouse model. Blood (2005) 1.11
Therapeutic vaccination with an autologous mRNA electroporated dendritic cell vaccine in patients with advanced melanoma. J Immunother (2011) 1.11
Fasting 2-deoxy-2-[18F]fluoro-D-glucose positron emission tomography to detect metabolic changes in pulmonary arterial hypertension hearts over 1 year. Ann Am Thorac Soc (2013) 1.11
Effects of the menstrual cycle on lung function variables in women with asthma. Am J Respir Crit Care Med (2009) 1.10
Chromatin remodeling agent trichostatin A: a key-factor in the hepatic differentiation of human mesenchymal stem cells derived of adult bone marrow. BMC Dev Biol (2007) 1.09
Disruption of the gamma-interferon signaling pathway at the level of signal transducer and activator of transcription-1 prevents immune destruction of beta-cells. Diabetes (2005) 1.09
Strategic plan for lung vascular research: An NHLBI-ORDR Workshop Report. Am J Respir Crit Care Med (2010) 1.09
Molecular regulation of monocyte chemoattractant protein-1 expression in pancreatic beta-cells. Diabetes (2003) 1.09
Vorinostat-induced bone loss might be related to drug toxicity. Bone (2013) 1.08
The involvement of osteopontin and its receptors in multiple myeloma cell survival, migration and invasion in the murine 5T33MM model. Br J Haematol (2006) 1.06
IGF-1 suppresses Bim expression in multiple myeloma via epigenetic and posttranslational mechanisms. Blood (2010) 1.04
Central role and mechanisms of β-cell dysfunction and death in friedreich ataxia-associated diabetes. Ann Neurol (2012) 1.02
Mediators and mechanisms of pancreatic beta-cell death in type 1 diabetes. Arq Bras Endocrinol Metabol (2008) 1.01
Notch signaling: a mediator of beta-cell de-differentiation in diabetes? Biochem Biophys Res Commun (2005) 1.01
Targeting the IGF-1R using picropodophyllin in the therapeutical 5T2MM mouse model of multiple myeloma: beneficial effects on tumor growth, angiogenesis, bone disease and survival. Int J Cancer (2007) 1.00
Bone marrow-derived mesenchymal stromal cells are attracted by multiple myeloma cell-produced chemokine CCL25 and favor myeloma cell growth in vitro and in vivo. Stem Cells (2012) 0.98
Unraveling the biology of multiple myeloma disease: cancer stem cells, acquired intracellular changes and interactions with the surrounding micro-environment. Bull Cancer (2008) 0.98
Epigenetic modulating agents as a new therapeutic approach in multiple myeloma. Cancers (Basel) (2013) 0.97
Extravasation and homing mechanisms in multiple myeloma. Clin Exp Metastasis (2007) 0.97
tRNA methyltransferase homolog gene TRMT10A mutation in young onset diabetes and primary microcephaly in humans. PLoS Genet (2013) 0.96
Activation of ATF4 mediates unwanted Mcl-1 accumulation by proteasome inhibition. Blood (2011) 0.96
The involvement of stromal derived factor 1alpha in homing and progression of multiple myeloma in the 5TMM model. Haematologica (2006) 0.96
Enhanced signaling downstream of ribonucleic Acid-activated protein kinase-like endoplasmic reticulum kinase potentiates lipotoxic endoplasmic reticulum stress in human islets. J Clin Endocrinol Metab (2010) 0.95
Multiple myeloma--an update on diagnosis and treatment. Eur J Haematol (2008) 0.95
The microenvironment and molecular biology of the multiple myeloma tumor. Adv Cancer Res (2011) 0.94
Bortezomib alone or in combination with the histone deacetylase inhibitor JNJ-26481585: effect on myeloma bone disease in the 5T2MM murine model of myeloma. Cancer Res (2009) 0.94
Resistance to type 2 diabetes mellitus: a matter of hormesis? Nat Rev Endocrinol (2011) 0.94
Impaired function of circulating CD34(+) CD45(-) cells in patients with proliferative diabetic retinopathy. Exp Eye Res (2010) 0.94
Multiple myeloma tumor progression in the 5T2MM murine model is a multistage and dynamic process of differentiation, proliferation, invasion, and apoptosis. Blood (2002) 0.93
Efficient differentiation of human embryonic stem cells into a homogeneous population of osteoprogenitor-like cells. Reprod Biomed Online (2008) 0.93
Generation of large numbers of dendritic cells in a closed system using Cell Factories. J Immunol Methods (2002) 0.93
Upregulation of miR-135b is involved in the impaired osteogenic differentiation of mesenchymal stem cells derived from multiple myeloma patients. PLoS One (2013) 0.92
An improved harvest and in vitro expansion protocol for murine bone marrow-derived mesenchymal stem cells. J Biomed Biotechnol (2010) 0.92
Angiogenic switch during 5T2MM murine myeloma tumorigenesis: role of CD45 heterogeneity. Blood (2003) 0.92
Inhibition of nuclear factor-kappaB or Bax prevents endoplasmic reticulum stress- but not nitric oxide-mediated apoptosis in INS-1E cells. Endocrinology (2009) 0.91
Effect of the HDAC inhibitor vorinostat on the osteogenic differentiation of mesenchymal stem cells in vitro and bone formation in vivo. Acta Pharmacol Sin (2013) 0.91
Dll1/Notch activation contributes to bortezomib resistance by upregulating CYP1A1 in multiple myeloma. Biochem Biophys Res Commun (2012) 0.90
Understanding the hypoxic niche of multiple myeloma: therapeutic implications and contributions of mouse models. Dis Model Mech (2012) 0.90
Synergistic induction of apoptosis in multiple myeloma cells by bortezomib and hypoxia-activated prodrug TH-302, in vivo and in vitro. Mol Cancer Ther (2013) 0.90
Pulmonary artery endothelium resident endothelial colony-forming cells in pulmonary arterial hypertension. Pulm Circ (2012) 0.90
Evidence that intracoronary-injected CD133+ peripheral blood progenitor cells home to the myocardium in chronic postinfarction heart failure. Exp Hematol (2007) 0.89
Pulmonary gas transfer related to markers of angiogenesis during the menstrual cycle. J Appl Physiol (1985) (2007) 0.89
Inhibition of p38alpha mitogen-activated protein kinase prevents the development of osteolytic bone disease, reduces tumor burden, and increases survival in murine models of multiple myeloma. Cancer Res (2007) 0.88